CUR vs. COEP, SNTI, NSTGQ, IKT, BCDA, ONVO, GENE, SRNE, PMCB, and TTNP
Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Coeptis Therapeutics (COEP), Senti Biosciences (SNTI), NanoString Technologies (NSTGQ), Inhibikase Therapeutics (IKT), BioCardia (BCDA), Organovo (ONVO), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), PharmaCyte Biotech (PMCB), and Titan Pharmaceuticals (TTNP). These companies are all part of the "medical" sector.
Neuralstem (NASDAQ:CUR) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.89, meaning that its share price is 189% less volatile than the S&P 500.
Neuralstem received 273 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 66.83% of users gave Neuralstem an outperform vote.
Neuralstem has higher revenue and earnings than Coeptis Therapeutics.
38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Coeptis Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Neuralstem's return on equity of -170.51% beat Coeptis Therapeutics' return on equity.
Coeptis Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 796.06%. Given Coeptis Therapeutics' higher possible upside, analysts clearly believe Coeptis Therapeutics is more favorable than Neuralstem.
In the previous week, Coeptis Therapeutics had 5 more articles in the media than Neuralstem. MarketBeat recorded 5 mentions for Coeptis Therapeutics and 0 mentions for Neuralstem. Neuralstem's average media sentiment score of 0.00 beat Coeptis Therapeutics' score of -0.10 indicating that Neuralstem is being referred to more favorably in the media.
Summary
Neuralstem beats Coeptis Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Neuralstem News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuralstem Competitors List
Related Companies and Tools
